SCT 400

Drug Profile

SCT 400

Alternative Names: Recombinant chimeric anti-CD20 monoclonal antibody - Sinocelltech; SCT-400

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sinocelltech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Non-Hodgkin's lymphoma

Most Recent Events

  • 06 Sep 2017 No development reported - Phase-II for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in China (IV)
  • 18 May 2016 Sinocelltech plans a phase III trial for Diffuse large B cell lymphoma (First-line therapy, Combination therapy) China (NCT02772822)
  • 27 May 2015 Phase-II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (IV) (NCT02456207)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top